

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**21-372/S008/S010**

**MEDICAL REVIEW(S)**

**Division of Gastroenterology Products  
Clinical Review**

Application Type NDA 21-372/S008, (b) (4) S010  
Submission Date 3 June 2007

PDUFA Goal Date 3 March 2008

Drug Aloxi® Palonosetron  
Therapeutic Class 5HT<sup>3</sup> Receptor Antagonist

Applicant Helsinn Healthcare SA  
Regulatory Contact Dr. Craig Lehmann  
August Consulting, Inc  
515 Capital of Texas Highway  
Austin, Texas 78746

Priority Designation S  
Formulation Intravenous  
Dosing Regimen 0.075 mg

Indication(s) Post operative nausea and vomiting (PONV):  
(b) (4)

Intended Population Adults

Reviewer Dr. Nancy F. Snow  
Medical Officer  
HFD-180

TABLE OF CONTENTS

<b>1</b>	<b>EXECUTIVE SUMMARY</b>	<b>5</b>
1.1	RECOMMENDATION ON REGULATORY ACTION	5
1.2	RECOMMENDATION ON POST MARKETING ACTIONS	6
1.2.1	Risk Management Activity	6
1.2.2	Required Phase 4 Commitments	6
1.2.3	Other Phase 4 Requests	6
1.3	SUMMARY OF CLINICAL FINDINGS	7
1.3.1	Brief Overview of Clinical Program	7
1.3.2	Efficacy	7
1.3.1	Safety	8
1.3.2	Dosing Regimen and Administration	9
1.3.3	Drug-Drug Interactions	9
1.3.4	Special Populations	10
<b>2</b>	<b>INTRODUCTION AND BACKGROUND</b>	<b>11</b>
2.1	PRODUCT INFORMATION	11
2.2	CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS	11
2.3	AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES	12
2.4	IMPORTANT ISSUES WITH PHARMACOLOGICALLY RELATED PRODUCTS	12
2.5	PRESUBMISSION REGULATORY ACTIVITY	12
2.6	OTHER RELEVANT BACKGROUND INFORMATION	13
<b>3</b>	<b>SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES</b>	<b>13</b>
3.1	CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE)	13
3.2	ANIMAL PHARMACOLOGY/TOXICOLOGY	14
<b>4</b>	<b>DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY</b>	<b>14</b>
4.1	SOURCES OF CLINICAL DATA	14
4.2	TABLES OF CLINICAL STUDIES	14
4.3	REVIEW STRATEGY	14
4.4	DATA QUALITY AND INTEGRITY	15
4.5	COMPLIANCE WITH GOOD CLINICAL PRACTICES	15
4.6	FINANCIAL DISCLOSURES	15
<b>5</b>	<b>CLINICAL PHARMACOLOGY</b>	<b>15</b>
5.1	PHARMACOKINETICS	15
5.2	PHARMACODYNAMICS	16
5.3	EXPOSURE-RESPONSE RELATIONSHIPS	16
<b>6</b>	<b>INTEGRATED REVIEW OF EFFICACY</b>	<b>16</b>
6.1	INDICATION; PONV (b) (4)	16
6.1.1	Methods	18
6.1.2	General Discussion of Endpoints	18
6.1.3	Study Design	20
6.1.4	Efficacy Findings	24
6.1.5	Clinical Microbiology	28
6.1.6	Efficacy Conclusions	28
<b>7</b>	<b>INTEGRATED REVIEW OF SAFETY</b>	<b>29</b>
7.1	METHODS AND FINDINGS	29
7.1.1	Deaths	30

7.1.2	Other Serious Adverse Events .....	30
7.1.3	Dropouts and Other Significant Adverse Events .....	33
7.1.4	Other Search Strategies.....	34
7.1.5	Common Adverse Events .....	34
7.1.6	Less Common Adverse Events .....	36
7.1.7	Laboratory Findings.....	36
7.1.8	Vital Signs .....	37
7.1.9	Electrocardiograms (ECGs).....	38
7.1.10	Immunogenicity .....	42
7.1.11	Human Carcinogenicity .....	42
7.1.12	Special Safety Studies.....	42
7.1.13	Withdrawal Phenomena and/or Abuse Potential.....	42
7.1.14	Human Reproduction and Pregnancy Data .....	42
7.1.15	Assessment of Effect on Growth.....	42
7.1.16	Overdose Experience .....	42
7.1.17	Post marketing Experience.....	43
7.2	ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS .....	43
7.2.1	Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure) Used to Evaluate Safety .....	43
7.2.2	Description of Secondary Clinical Data Sources Used to Evaluate Safety .....	45
7.2.3	Adequacy of Overall Clinical Experience .....	47
7.2.4	Adequacy of Special Animal and/or In Vitro Testing .....	47
7.2.5	Adequacy of Routine Clinical Testing.....	47
7.2.6	Adequacy of Metabolic, Clearance, and Interaction Workup.....	47
7.2.7	Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugs in the Class Represented by the New Drug; Recommendations for Further Study.....	47
7.2.8	Assessment of Quality and Completeness of Data .....	48
7.2.9	Additional Submissions, Including Safety Update .....	48
7.3	SUMMARY OF SELECTED DRUG-RELATED ADVERSE EVENTS, IMPORTANT LIMITATIONS OF DATA, AND CONCLUSIONS .....	48
7.4	GENERAL METHODOLOGY .....	48
7.4.1	Pooling Data across Studies to Estimate and Compare Incidence .....	48
7.4.2	Explorations for Predictive Factors .....	48
7.4.3	Causality Determination .....	49
8	ADDITIONAL CLINICAL ISSUES .....	49
8.1	DOSING REGIMEN AND ADMINISTRATION .....	49
8.2	DRUG-DRUG INTERACTIONS .....	49
8.3	SPECIAL POPULATIONS.....	50
8.4	PEDIATRICS.....	50
8.5	ADVISORY COMMITTEE MEETING.....	50
8.6	LITERATURE REVIEW .....	51
8.7	POST MARKETING RISK MANAGEMENT PLAN .....	51
8.8	OTHER RELEVANT MATERIALS .....	51
9	OVERALL ASSESSMENT.....	51
9.1	CONCLUSIONS .....	51
9.2	RECOMMENDATION ON REGULATORY ACTION .....	51
9.3	RECOMMENDATION ON POST MARKETING ACTIONS.....	52
9.3.1	Risk Management Activity .....	52
9.3.2	Required Phase 4 Commitments.....	52
9.3.3	Other Phase 4 Requests.....	52
9.4	LABELING REVIEW .....	52

Clinical Review  
Nancy F. Snow  
NDA 21-372/S-008  
Palonosetron, Aloxi®

---

<b>10 APPENDICES .....</b>	<b>53</b>
10.1 REVIEW OF INDIVIDUAL STUDY REPORTS .....	53
10.2 LINE-BY-LINE LABELING REVIEW.....	53
<b>REFERENCES .....</b>	<b>54</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.